Maitines septiembre de 2011 Francisco Jorquera Plaza
|
|
- Hillary Gallagher
- 5 years ago
- Views:
Transcription
1 Bringing Into Focus: A Practical Guide to Using Virologic and Serologic Tests in the Management of Hepatitis B Maitines septiembre de 2011 Francisco Jorquera Plaza
2 2.000 millones de personas infectadas por el VHB en todo el mundo Casi la mitad de la población mundial vive en áreas con prevalencias elevadas de VHB mill. de personas con evidencia de infección por VHB El 15 25% muere por cirrosis o cáncer de hígado Población mundial: millomes 350 millones con infección crónica por VHB 1. Adaptado de Lavanchy D. J Viral Hepatitis 2004;11:
3 Geographic Distribution of Chronic HBV Infection 7.2% HBsAg Prevalence 8% (high) 2% to 7% (intermediate) < 2% (low) Weinbaum CM, et al. MMWR Recomm Rep. 2008;57(RR-8):1-20. Liang X, Bi S, et al. Vaccine. 2009;27:
4 The HBV Iceberg Clinical populations are the tip of the iceberg Individuals in treatment are the tip of the tip Population-based studies allow us to look at the whole iceberg 2 million individuals in the US have chronic HBV infection 1.4 million are unaware of their chronic HBV infection 50,000 receive treatment 150,000 are diagnosed in care and meet treatment 300,000 are guidelines diagnosed in care 500,000 are potentially eligible for treatment 600,000 are aware of their chronic HBV infection Asia has been the place for these Cohen C, et al. J Viral Hepatitis. 2011;18: Graphic reproduced with permission.
5 Groups at High Risk for HBV Infection Who Should Be Screened Persons born in geographic regions with HBsAg prevalence of 2% US-born persons, not vaccinated as infants, whose parents were born in geographic regions with HBsAg prevalence of 8% Persons with chronically elevated aminotransferases Persons needing immunosuppressive therapy Men who have sex with men Persons with multiple sexual partners or history of sexually transmitted disease Inmates of correctional facilities Persons who have ever used injection drugs Dialysis patients HIV- or HCV-infected individuals Pregnant women Family members, household members, and sexual contacts of HBV-infected persons Lok AS, et al. Hepatology. 2009;50:
6 Assessing Patient History and Current Presentation Age Duration of disease Family history of HCC Alcohol use Smoking history Fatty liver disease, diabetes mellitus, metabolic syndrome Patient motivation, compliance, adherence Comorbidities: renal, bone Cost of testing and treatment/insurance
7 Hepatitis B Serology: First Phase Testing AASLD guidelines recommend HBsAg and anti-hbs testing for all patients HBsAg Protein on surface of HBV detected during acute or chronic HBV infection Presence indicates an individual is INFECTED OR INFECTIOUS Anti-HBs Presence indicates recovery and IMMUNITY from HBV infection Also develops following vaccination against hepatitis B Total anti-hbc can be used as alternative; those testing positive should be tested for HBsAg and anti-hbs Appears at the onset of symptoms in acute hepatitis and persists for life Presence indicates EXPOSURE (previous or ongoing infection with HBV) Lok AS, et al. Hepatology. 2009;50:
8 Why Do We Need to Do Anti-HBc Testing? Decide who needs HBV vaccine Patients testing negative for HBsAg but positive for anti-hbc in regions of high HBV prevalence have had exposure due to natural infection; therefore, no need to vaccinate* Chemoprophylaxis for HBV reactivation Immunocompromised patients can experience reactivation of HBV if anti-hbc is positive Assess risk of donor HBV transmission Recipients of livers from anti-hbc positive patients are at risk for HBV transmission *However, one of the possibilities for isolated HBcAb (total) is the possibility of false positive in low prevalence areas or in individuals with no risk factors for HBV, in which case they may need to be vaccinated.
9 Hepatitis B Serology: IgM anti-hbc IgM anti-hbc (IgM antibody to hepatitis B core antigen) [1] Presence indicates acute infection (negative in chronic infection) Positivity indicates recent infection with HBV ( 6 mos) Occasionally occurs in the presence of a severe flare of chronic HBV disease Small minority of pts with chronic HBV are IgM anti- HBc+, indicating higher risk for progression to cirrhosis or HCC [2] 1. CDC. Hepatitis B FAQs for health professionals. Available at: HBV/HBVfaq.htm. 2. Colloredo MG, et al. Arch Virol Suppl. 1993;8:
10 Interpretation of Serologic Results HBsAg Total Anti-HBc IgM Anti-HBc Anti-HBs Interpretation Negative Negative NA Negative Susceptible; offer vaccination Negative Positive NA Positive Immune due to natural infection Negative Negative NA Positive Immune due to hepatitis B vaccination Positive Positive Negative Negative Chronic HBV infection Positive Positive Positive Negative Acute HBV infection Negative Positive NA Negative Unclear; could be any one of the following: 1. Resolved infection (most common) 2. False-positive anti-hbc; susceptible 3. Low-level chronic infection 4. Resolving acute infection CDC. Hepatitis B FAQs for health professionals. Available at:
11 Initial Testing in Patients Diagnosed With Chronic HBV Testing for Patients Who Are HBsAg Positive [1] Lab tests to assess liver disease: hepatic panel, and INR (prothrombin time) Tests for HBV replication: HBeAg/anti-HBe, HBV DNA Tests to rule out viral coinfections: anti-hcv, anti-hdv (in persons from countries where HDV infection is common and in those with history of injection drug use), and anti-hiv in those at risk Tests for screening and surveillance for HCC: AFP and ultrasound as appropriate Consider liver biopsy to grade and stage liver disease: for patients who meet criteria for chronic hepatitis Consider core and precore assays and testing for HBV genotype CDC guidelines recommend HIV testing in ALL chronic HBV patients [2] 1. Lok AS, et al. Hepatology. 2009;50: Weinbaum CM, et al. MMWR Recomm Rep. 2008;57(RR-8):1-20.
12 Hepatitis B Serology: Determining HBeAg Status in CHB Patients HBeAg Secreted coproduct of nucleocapsid gene of HBV found in serum during acute and chronic HBV with wild-type infection Presence indicates replicating natural variant virus and often associated with high HBV DNA levels Anti-HBe Produced by immune system temporarily during acute HBV infection or consistently during or after a burst in viral replication in setting of wild-type infection clearance Conversion from HBeAg positive to anti-hbe positive a predictor of Long-term clearance of HBV in patients undergoing antiviral therapy and indicates lower levels of HBV or Emergence of precore, mixed, or core promoter mutant infection and transition to HBeAg-negative disease
13 HBV Variants Wild type Unmutated HBeAg-positive hepatitis Mixed infection with Basal core promoter mutations (44% of US patients) [1,2] Precore mutations (27% of US patients) [2] Precore and core promoter mutations [3] Eventually abolishes HBeAg production (HBeAg-negative CHB) Genotypes Treatment-induced mutations 1. Buckwold VE, et al. J Virol. 1996;70: Chu CJ, et al. Gastroenterology. 2003;125: Hunt CM, et al. Hepatology. 2000; 31:
14 Natural History of HBV Infection Childhood > 95% Immune tolerance Adulthood < 5% HBeAg+ CHB HBeAg- CHB Inactive carrier Cirrhosis Chen DS, et al. J Gastroenterol Hepatol. 1993;8: Seeff L, et al. N Engl J Med. 1987;316:
15 High Risk of Cirrhosis in Asians & Patients With Vertically Transmitted Disease The lifetime risk of cirrhosis or cancer in a person who is HBsAg positive is 20% to 30% Risk is lower for women Risk is highest for men Fattovich G, et al. Am J Gastroenterol. 2002;97: Fattovich G, et al. Gastroenterology. 2004;11;27:S35-S50. McMahin BJ. Hepatology. 2009;49:S45-S55.
16 HBV Classified Into 10 Genotypes Genotype A B and C D E F G H I J Geographic distribution North America, northern Europe, India, and Africa Asia Southern Europe, Middle East, and India West Africa and South Africa Central and South America United States and Europe Central America and California Vietnam Japan Fung SK, et al. 2004;40: Norder H, et al. Intervirology. 2004;47: Tuan Huy TT, et al. J Virol. 2008;82: Tatematsu K, et al. J Virol. 2009;83:
17 Why Test for HBV Genotype? Differences in natural history and treatment responsiveness B is associated with less active disease, slower progression, and lower incidence of HCC than C C has higher risk of HCC and cirrhosis A and B respond better to IFN than C and D F is associated with fulminant liver disease; rare Current guidelines indicate that additional data are needed before testing for genotypes in clinical practice is recommended Lok AS, et al. Hepatology. 2009;50: EASL. J Hepatol. 2009;50:
18 Summary: Tests for Initial Evaluation and Diagnosis of HBV Clinical assessment for HBV disease is a multistep process History Physical exam Serologic tests Nucleic acid tests Liver biochemistries including liver synthetic tests HCC biomarkers Imaging
19 Parameters Used to Determine Candidates for Treatment of HBV ALT New normal or healthy ALT: < 30 U/L for men and < 19 U/L for women [1] Presence of 1 normal value does not exclude significant disease or subsequent complications HBV DNA Predicts development of cirrhosis and HCC [2,3] Interpret in conjunction with ALT and/or histology Liver biopsy Useful in situations where ALT or HBV DNA do not provide clear guidelines for treatment [1] 1. Lok AS et al. Hepatology. 2009;50: Iloeje UH et al. Gastroenterology. 2006;130: Chen CJ et al. JAMA. 2006;295:65-73.
20 Transmission of HBV Is Proportional to HBV DNA Level Horizontal Transmission Higher DNA, higher risk Vertical Transmission Infected person Recipient Mother > IU/mL Child to child Contaminated needles Sexual Healthcare worker Transfusion Hemodialysis No clear risk factors in 20% to 30% of patients Infant Perinatal Common in regions with HBsAg prevalence of > 2% CDC. Hepatitis B Information for the Public. Fact sheet. Lee WM. N Engl J Med. 1997;337: Lavanchy D. J Viral Hepat. 2004;11:
21 Natural History of HBV: Directly Related to HBV DNA Level 5% to 10% Liver cancer (HCC) Chronic infection 30% 10% to 15% in 5 yrs Cirrhosis 23% in 5 yrs Liver transplantation* Death Acute flare Liver failure *HBV is the 6th leading cause of liver transplantation in the United States. Fattovich G, et al. Gastroenterology. 2004;127:S35-S50. Seeff LB, et al. Hepatology. 2001;33: Torresi J, et al. Gastroenterology. 2000;118:S83-S103. Fattovich G, et al. Hepatology. 1995;21:77-82.
22 Treatment Criteria for Chronic Hepatitis B: Comparison of Guidelines Guidelines HBeAg Positive HBeAg Negative HBV DNA, IU/mL ALT HBV DNA, IU/mL EASL 2009 [1] > 2000 > ULN > 2000 > ULN APASL 2008 [2] 20,000 > 2 x ULN 2000 > 2 x ULN AASLD 2009 [3] > 20,000 NIH Consensus Conference > 20, [4] US Algorithm 2008 [5] 20,000 > 2 x ULN or positive biopsy > 2 x ULN or positive biopsy > ULN or positive biopsy 20,000 20, ALT 2 x ULN or positive biopsy 2 x ULN or positive biopsy > ULN or positive biopsy 1. EASL. J Hepatol. 2009;50: Liaw YF, et al. Hepatol Int. 2008;3: Lok AS, et al. Hepatology. 2009;50: Degerekin B, et al. Hepatology. 2009;S129-S Keefe EB. Clin Gastroenterol Hepatol. 2008;6:
23 Clinical Profiles of Chronic HBV Infection Parameter Typical HBV DNA, IU/mL Immune Tolerance Immune Active/ HBeAg-Positive CHB Nonreplicative (Inactive Carrier) HBeAg- Negative CHB > 200, ,000-2 x 10 9 < x 10 7 HBeAg Positive Positive Negative Negative ALT Other observations Treatment candidate? Normal Liver biopsy typically normal or minimal findings Elevated or fluctuating Active inflammation on liver biopsy Normal HBsAg may become undetectable Elevated or fluctuating Active inflammation on liver biopsy No Yes No Yes Lok AS, et al. Hepatology. 2009;50:
24 Noninvasive Serum-Based Tests for Detection of Fibrosis Test FibroTest FibroSpect II FibroSURE APRI Forns fibrosis index FIB-4 HepaScore Fibrometer Parameters Measured α2-macroglobulin, haptoglobin, GGT, total bilirubin, and apolipoprotein A1 α2-macroglobulin, hyaluronic acid, and tissue inhibitor of metalloproteinase-1 α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, total cholesterol, triglycerides, and fasting AST-to-platelets glucose ratio index Age, platelet count, GGT, cholesterol Platelets, ALT, AST, and age α2-macroglobulin, GGT, hyaluronic acid, and total bilirubin Age, sex, α2-macroglobulin, hyaluronic acid, platelets, prothrombin index, AST, and urea No guidelines currently recommend routine clinical use of noninvasive methods for the detection of fibrosis
25 Transient Elastography: A Potential Noninvasive Alternative to Liver Biopsy Elastography Ultrasound transducer probe induces elastic wave through the liver Velocity of the wave is evaluated in a region located from cm below the skin surface Whereas a liver biopsy is able to examine 1/50,000 of the liver, elastography is able to examine 1/500 of the liver Despite extensive research and progress, no guidelines recommend transient elastography as alternative to liver biopsy for CHB Effective at discriminating between severe and mild fibrosis but less effective at distinguishing intermediate levels of fibrosis [1-2] MRI and MR spectroscopy other potential noninvasive tests to detect cirrhosis [3] 1. Chan HL, et al. J Viral Hepat. 2009;16: Marcellin P, et al. Liver Int. 2009;29: Friedrich-Rust M, et al. J Clin Gastroenterol. 2010;44:58-65.
Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationOutline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018
Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial
More informationMarch 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D
March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationHBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationHepatitis B screening and surveillance in primary care
Hepatitis B screening and surveillance in primary care Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationBible Class: Hepatitis B Virus Infection
Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:
More informationEAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationAPPROACH TO A PATIENT WITH CHRONIC HEPATITIS B INFECTION. Dr. Mohammad Zahiruddin Associate Professor Department of Medicine Dhaka Medical College
APPROACH TO A PATIENT WITH CHRONIC HEPATITIS B INFECTION Dr. Mohammad Zahiruddin Associate Professor Department of Medicine Dhaka Medical College Mr. Alam is a 32 yr old welder, who has been selected for
More informationA Message to Presenters
A Message to Presenters As a healthcare professional speaking on behalf of Bristol-Myers Squibb (BMS), any presentation you make on our behalf must be consistent with the current FDA-approved product labeling
More informationIN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST
IN THE NAME OF GOD AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL D r. MANIJE DEZFULI INFECTIOUS DISEASES SPECIALIST Acute Viral Hepatitis The Anatomy of the Liver Hepatic Physiology Liver: Largest solid organ
More informationNATURAL HISTORY OF HEPATITIS B
NATURAL HISTORY OF HEPATITIS B AND DIAGNOSTIC: STATE OF THE ART O. BAHRI LABORATORY OF MEDICAL BIOLOGY AZIZA OTHMANA HOSPITAL TUNIS, TUNISIA The 2 nd Congress of The Federation of Arab Societies of Clinical
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationNorth Africa) The prevalence of CHB varies widely across EMEA (Europe, Middle East & 8% High 2 8% Intermediate <2% Low
The prevalence of CHB varies widely across EMEA (Europe, Middle East & North Africa) 8% High 2 8% Intermediate
More informationClinical dilemmas in HBeAg-negative CHB
Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department
More informationGAZETTE COMMON GROUND. CHB: A significant and prevalent disease in the US and worldwide. Inside. Screening, diagnosis, and evaluation
VOL III/III COMMON GROUND GAZETTE Inside CASE 1: Screening, diagnosis, and evaluation P. 1 CASE 2: Initiating treatment P. 4 CASE 3: Managing antiviral resistance P. 5 CASE 4: Achieving the maximum effect
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationClinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL
Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationCITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationClinical cases: HIV/HCV coinfection
Clinical cases: HIV/HCV coinfection José Vicente Fernández-Montero Hospital Carlos III, Madrid Case #1 General considerations about antiviral therapy CASE # 1 43 year-old, male patient Former IDU No prior
More informationHepatitis B in Africa: Epidemiology, Pathophysiology and Challenges
Gilead-sponsored symposium at the 11th INTEREST Workshop 2017 Hepatitis B in Africa: Epidemiology, Pathophysiology and Challenges Ponsiano Ocama Department of Medicine Makerere University College of Health
More informationHEPATITIS B: WHO AND WHEN TO TREAT?
HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091608 Age 26 Years Gender Female 30/8/2017 92900AM 30/8/2017 94717AM 31/8/2017 90216AM Ref By Final HEATITIS ACUTE VIRUS CONFIRMATION HEATITIS A ANTIBODY (ANTI HAV),
More informationThe ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses
The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection
More informationUpdate on Hepatitis B and Hepatitis C
Update on Hepatitis B and Hepatitis C Catherine Stedman Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch Disclosures I have the following financial relationships
More informationEmerging Challenges In Primary Care: Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How
Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor
More informationWorld Health Organization. Western Pacific Region
Standard modules for HBV 1 HBV Module 1 Hepatitis B serological markers and virology 2 Acute hepatitis HAV HBV HCV HDV HEV Case fatality Case fatality Uncommon increases with increases with age age Superinfection
More informationS401- Updates in the Treatments of Hepatitis B & C
S401- Updates in the Treatments of Hepatitis B & C Ruben Gonzalez-Vallina, MD Director of Gastroenterology Outpatient Initiatives Miami Children s Hospital Miami, Florida Disclosure of Relevant Relationship
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationNon-Invasive Testing for Liver Fibrosis
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview
More informationProfessor Vincent Soriano
Five Nations Conference on HIV and Hepatitis in partnership with Professor Vincent Soriano Hospital Carlos III, Madrid, Spain Professor Vincent Soriano in partnership with Hospital Carlos III, Madrid,
More informationEmerging Challenges In Primary Care: 2015
Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor of Clinical
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationModule 1 Introduction of hepatitis
Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand
More informationEmerging Challenges In Primary Care: 2015
Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor of Clinical
More informationClinical Case Maria Butí, MD, PhD
Clinical Case Maria Butí, MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital 1 Clinical Case 70 year-old male Smoker, no alcohol intake No risk factors Diabetes Mellitus treated with
More informationBeyond the Tip of the Iceberg: Strategies to Ensure Optimal HBV Screenin g, Diagnosis, and Initial Therapy
: Strategies to Ensure Optimal HBV Screenin g, Diagnosis, and Initial Therapy Sunday, November 1, 2009 Back Bay Ballroom Sheraton Boston Hotel Boston, Massachusetts This program is supported by an educational
More informationHepatitis B Diagnosis and Management. Marion Peters University of California San Francisco
Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage
More informationNIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:
ABC s of Hepatitis C Treatment Today Elizabeth N. Britton, MSN, FNP-BC Hepatology Services Louisiana State University Health Sciences Center ebritt@lsuhsc.edu ANAC CONFERENCE -TUCSON NOV 2012 Hepatitis
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationWhat have we learned from HBV clinical cohorts?
PHC 2015: Hepatitis B What have we learned from HBV clinical cohorts? Jia-Horng Kao MD, Ph D Graduate Institute of Clinical Medicine, Hepatitis Research Center, Department of Internal Medicine, National
More informationARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:xxx REVIEW A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update EMMET B. KEEFFE,* DOUGLAS T. DIETERICH,
More informationPrise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques
Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques Future Complications of Darius Moradpour Service de Gastro-entérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationEpidemiology of hepatitis B and D in Greece
Epidemiology of hepatitis B and D in Greece George V. Papatheodoridis Assistant Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University Medical School, Hippokration
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationThe Hepatitis B-e antigen-positive
The Hepatitis B-e antigen-positive Dental Student Developing an Equitable Policy Hepatitis B Virus Serology 1 HBsAg A protein on the surface of HBV; it can be detected in high levels in serum during acute
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More informationSerum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013
Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationACTIVITY DISCLAIMER. Kurt Cook, MD, MSc DISCLOSURE. Audience Engagement System. Learning Objectives
On the Liver Disease Front Lines: Hepatitis A, B and C Prevention and Treatment Kurt Cook, MD, MSc ACTIVITY DISCLAIMER The material presented here is being made available by the American Academy of Family
More informationWhite Nights of Hepatology 2016
White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow
More informationDiagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)
Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationMonitoring Hepatitis C
Monitoring Hepatitis C Section Six Monitoring Hepatitis C Screening for hepatitis C is not routinely done, so you may have to request a test from your medical provider. This usually involves an antibody
More informationMedia centre. WHO Hepatitis B. Key facts. 1 of :12 AM.
1 of 5 2013-08-02 7:12 AM Media centre Hepatitis B Share Print Fact sheet N 204 Updated July 2013 Key facts Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic
More informationDr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1
Dr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1 No disclosures. 15/09/2018 2 Sub-Saharan Africa (SSA) has a high burden of morbidity and mortality resulting
More informationFor now, do not stop NUCs PHC R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit
For now, do not stop NUCs PHC 2019 R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit Disclosure PI: Clinical Trials -ABBVIE -INTERCEPT -GILEAD -Novartis -BMS
More informationINTERPRETING HEPATITIS B SEROLOGY
INTERPRETING HEPATITIS B SEROLOGY RECOMMENDED WORDING FOR NATIONAL LABORATORIES TO REPORT HEPATITIS B DIAGNOSTIC TEST RESULTS THIS DOCUMENT HAS BEEN ENDORSED BY: Australasian Society for HIV Medicine,
More informationPrimary Care for Hepatitis B and C:
Primary Care for Hepatitis B and C: Clinical Tools for Efficient Management Estimated 17 Million Persons With HCV Infection Worldwide 3-4 million newly infected each yr worldwide Advances in Internal Medicine
More informationManagement of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER
Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines
More informationEliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific
Eliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific Augustina Manuzak, MD, MPH, PhD Augustina.manuzak@doh.hawaii.gov 10/10/2012
More informationViral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a
Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes
More informationViral Hepatitis. Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP
Viral Hepatitis Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP Viral hepatitis Viral hepatitis must be considered in any patient presenting with hepatitis on LFTs (high
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationHepatitis B Epidemiology and Prevention in the Elimination Era John W. Ward, MD
Hepatitis B Epidemiology and Prevention in the Elimination Era John W. Ward, MD Director, Program for Viral Hepatitis Elimination, Task Force for Global Health Senior Scientist, National Center for HIV/AIDS,
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationAASLD PRACTICE GUIDELINE UPDATE Chronic Hepatitis B: Update 2009
AASLD PRACTICE GUIDELINE UPDATE Chronic Hepatitis B: Update 2009 Anna S. F. Lok 1 and Brian J. McMahon 2 The 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More information2/12/2018. David M. Fettig, M.D. Birmingham Gastroenterology Associates. Outline basics of Hepatitis B. Phases of Chronic Hepatitis B
David M. Fettig, M.D. Birmingham Gastroenterology Associates Outline basics of Hepatitis B Phases of Chronic Hepatitis B Evaluation of Chronic Hepatitis B Treatment of Chronic Hepatitis B Special Populations
More informationFaculty: Hannah M. Lee, MD Geneve Allison, MD
pmicme Updates April 11, 2012 Anaheim, California Faculty: Hannah M. Lee, MD Geneve Allison, MD Session 3: SCALE HBV: Screening, Counseling and Linkage to Care Education Learning Objectives 1. Apply the
More information